查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1378781

高血脂藥物市場：2023-2028年全球產業趨勢、佔有率、規模、成長、機會與預測

Hyperlipidemia Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日期: | 出版商: IMARC | 英文 142 Pages | 商品交期: 2-3個工作天內

價格

概要

2022年全球高血脂藥物市場規模達222億美元。展望未來， IMARC Group預計到2028年市場規模將達到252億美元，2022-2028年複合年成長率（CAGR）為2.1%。

高血脂或高膽固醇是指以血液中高脂肪含量為特徵的醫學疾病。脂質和/或脂蛋白水平異常升高可導致中風、週邊血管疾病、動脈粥狀硬化、糖尿病、肥胖、高血壓和心血管疾病。它通常是由遺傳因素、不健康的生活方式和飲食不當引起的。一些常用的高血脂藥物包括他汀類藥物、前蛋白轉化酶枯草桿菌蛋白酶/Kexin 9 型(PCSK9) 抑制劑、膽汁酸螯合劑、纖維酸衍生物或貝特類藥物以及組合和其他降血脂藥物。這些藥物可降低肝臟中膽固醇的產生水平，同時進一步將其從血液中清除。

全球高血脂症盛行率不斷上升是推動市場成長的關鍵因素之一。此外，老年人口的增加也推動了市場的成長，老年人口更容易罹患高膽固醇和心血管疾病。與此一致的是，大眾健康意識的提高以及對高膽固醇血症可用治療替代方案的認知不斷增強也有利於市場的成長。此外，各種技術進步，例如具有增強功效的新型藥物類別的開發，也是其他生長誘導因素。這些藥物可改善內皮功能和動脈粥狀硬化斑塊的穩定性，並將對細胞的發炎和損傷降至最低。其他因素，包括生物醫學領域廣泛的研發（R＆D）活動，以及全球醫療保健基礎設施的整體改善，預計將進一步推動市場發展。

本報告回答的關鍵問題

  • 2022年全球高血脂症藥物市場規模？
  • 2023-2028年全球高血脂藥物市場的預期成長率是多少？
  • 推動全球高血脂藥物市場的關鍵因素是什麼？
  • COVID-19對全球高血脂藥物市場有何影響？
  • 全球高血脂藥物市場按藥物類型分類是怎樣的？
  • 基於最終用戶的全球高血脂藥物市場的詳細情形如何？
  • 全球高血脂藥物市場的重點區域有哪些？
  • 全球高血脂藥物市場的主要參與者/公司有哪些？

目錄

第 1 章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球高血脂藥物市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：按藥物類型分類的市場細分

  • 他汀類藥物
    • 市場走向
    • 市場預測
  • 膽汁酸螯合劑
    • 市場走向
    • 市場預測
  • 膽固醇吸收抑制劑
    • 市場走向
    • 市場預測
  • PCSK9 抑制劑
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 7 章：最終用戶的市場區隔

  • 醫院
    • 市場走向
    • 市場預測
  • 診所
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 8 章：按地區分類的市場區隔

  • 北美洲
    • 美國
      • 市場走向
      • 市場預測
    • 加拿大
      • 市場走向
      • 市場預測
  • 亞太地區
    • 中國
      • 市場走向
      • 市場預測
    • 日本
      • 市場走向
      • 市場預測
    • 印度
      • 市場走向
      • 市場預測
    • 韓國
      • 市場走向
      • 市場預測
    • 澳洲
      • 市場走向
      • 市場預測
    • 印尼
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 歐洲
    • 德國
      • 市場走向
      • 市場預測
    • 法國
      • 市場走向
      • 市場預測
    • 英國
      • 市場走向
      • 市場預測
    • 義大利
      • 市場走向
      • 市場預測
    • 西班牙
      • 市場走向
      • 市場預測
    • 俄羅斯
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 拉丁美洲
    • 巴西
      • 市場走向
      • 市場預測
    • 墨西哥
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 中東和非洲
    • 市場走向
    • 按國家/地區分類的市場細分
    • 市場預測

第 9 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 10 章：價值鏈分析

第 11 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 12 章：價格分析

第13章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Amgen Inc.
    • AstraZeneca Plc
    • Daiichi Sankyo Company Limited
    • Eli Lilly and Company
    • Esperion Therapeutics Inc.
    • GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc)
    • Immuron Limited
    • Ionis Pharmaceuticals Inc.
    • Merck & Co. Inc.
    • Pfizer Inc.
    • Sanofi SA
Product Code: SR112023A2685

Abstract

The global hyperlipidemia drugs market size reached US$ 22.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 25.2 Billion by 2028, exhibiting a growth rate (CAGR) of 2.1% during 2022-2028.

Hyperlipidemia, or high cholesterol, refers to a medical ailment characterized by high levels of fats in the bloodstream. It is the abnormal elevation of lipids and/or lipoprotein levels that can lead to stroke, peripheral vascular disease, atherosclerosis, diabetes, obesity, hypertension, and cardiovascular diseases. It is usually caused by genetic factors, unhealthy lifestyles and inadequate diet. Some of the commonly used hyperlipidemia drugs include statins, Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors, bile acid sequestrants, fibric acid derivatives or fibrates and combination and miscellaneous antihyperlipidemic agents. These drugs reduce cholesterol production levels in the liver while further removing it from the bloodstream.

The increasing prevalence of hyperlipidemia across the globe represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to high levels of cholesterol and cardiovascular diseases, is also driving the market growth. In line with this, rising health consciousness among the masses and growing awareness regarding the available treatment alternatives for hypercholesterolemia is also favoring the market growth. Additionally, various technological advancements, such as the development of novel drug classes with enhanced efficacy, are acting as other growth-inducing factors. These drugs offer improved endothelial function and stability of atherosclerotic plaques and cause minimal inflammation and damage to the cells. Other factors, including the extensive research and development (R&D) activities in the field of biomedical sciences, along with overall improvements in the healthcare infrastructure across the globe, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global hyperlipidemia drugs market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on drug type and end user

Breakup by Drug Type:

Statins

Bile Acid Sequestrants

Cholesterol Absorption Inhibitors

PCSK9 Inhibitors

Others

Breakup by End User:

Hospitals

Clinics

Others

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Amgen Inc., AstraZeneca PLC, Daiichi Sankyo Company Limited, Eli Lilly and Company, Esperion Therapeutics Inc., GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc), Immuron Limited, Ionis Pharmaceuticals Inc., Merck & Co. Inc., Pfizer Inc. and Sanofi S.A.

Key Questions Answered in This Report

  • 1. What was the size of the global hyperlipidemia drugs market in 2022?
  • 2. What is the expected growth rate of the global hyperlipidemia drugs market during 2023-2028?
  • 3. What are the key factors driving the global hyperlipidemia drugs market?
  • 4. What has been the impact of COVID-19 on the global hyperlipidemia drugs market?
  • 5. What is the breakup of the global hyperlipidemia drugs market based on the drug type?
  • 6. What is the breakup of the global hyperlipidemia drugs market based on the end user?
  • 7. What are the key regions in the global hyperlipidemia drugs market?
  • 8. Who are the key players/companies in the global hyperlipidemia drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hyperlipidemia Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Statins
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Bile Acid Sequestrants
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Cholesterol Absorption Inhibitors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 PCSK9 Inhibitors
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by End User

  • 7.1 Hospitals
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Clinics
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Amgen Inc.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 AstraZeneca Plc
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Daiichi Sankyo Company Limited
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 Eli Lilly and Company
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 Esperion Therapeutics Inc.
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
    • 13.3.6 GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc)
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 Immuron Limited
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
    • 13.3.8 Ionis Pharmaceuticals Inc.
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis
    • 13.3.9 Merck & Co. Inc.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Pfizer Inc.
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis
    • 13.3.11 Sanofi S.A.
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
      • 13.3.11.3 Financials
      • 13.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Hyperlipidemia Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Hyperlipidemia Drugs Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Hyperlipidemia Drugs Market: Breakup by Drug Type (in %), 2022
  • Figure 4: Global: Hyperlipidemia Drugs Market: Breakup by End User (in %), 2022
  • Figure 5: Global: Hyperlipidemia Drugs Market: Breakup by Region (in %), 2022
  • Figure 6: Global: Hyperlipidemia Drugs Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 7: Global: Hyperlipidemia Drugs (Statins) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 8: Global: Hyperlipidemia Drugs (Statins) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 9: Global: Hyperlipidemia Drugs (Bile Acid Sequestrants) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 10: Global: Hyperlipidemia Drugs (Bile Acid Sequestrants) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 11: Global: Hyperlipidemia Drugs (Cholesterol Absorption Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 12: Global: Hyperlipidemia Drugs (Cholesterol Absorption Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 13: Global: Hyperlipidemia Drugs (PCSK9 Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 14: Global: Hyperlipidemia Drugs (PCSK9 Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 15: Global: Hyperlipidemia Drugs (Other Drug Types) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 16: Global: Hyperlipidemia Drugs (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 17: Global: Hyperlipidemia Drugs (Hospitals) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 18: Global: Hyperlipidemia Drugs (Hospitals) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 19: Global: Hyperlipidemia Drugs (Clinics) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 20: Global: Hyperlipidemia Drugs (Clinics) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 21: Global: Hyperlipidemia Drugs (Other End Users) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 22: Global: Hyperlipidemia Drugs (Other End Users) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 23: North America: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 24: North America: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 25: United States: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 26: United States: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 27: Canada: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 28: Canada: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 29: Asia Pacific: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 30: Asia Pacific: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 31: China: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 32: China: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 33: Japan: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 34: Japan: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 35: India: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 36: India: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 37: South Korea: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 38: South Korea: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 39: Australia: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 40: Australia: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 41: Indonesia: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 42: Indonesia: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 43: Others: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 44: Others: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 45: Europe: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 46: Europe: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 47: Germany: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 48: Germany: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 49: France: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 50: France: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 51: United Kingdom: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 52: United Kingdom: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 53: Italy: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 54: Italy: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 55: Spain: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 56: Spain: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 57: Russia: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 58: Russia: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 59: Others: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 60: Others: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 61: Latin America: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 62: Latin America: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 63: Brazil: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 64: Brazil: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 65: Mexico: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 66: Mexico: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 67: Others: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 68: Others: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 69: Middle East and Africa: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 70: Middle East and Africa: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 71: Global: Hyperlipidemia Drugs Industry: SWOT Analysis
  • Figure 72: Global: Hyperlipidemia Drugs Industry: Value Chain Analysis
  • Figure 73: Global: Hyperlipidemia Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Hyperlipidemia Drugs Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Hyperlipidemia Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2023-2028
  • Table 3: Global: Hyperlipidemia Drugs Market Forecast: Breakup by End User (in Million US$), 2023-2028
  • Table 4: Global: Hyperlipidemia Drugs Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 5: Global: Hyperlipidemia Drugs Market Structure
  • Table 6: Global: Hyperlipidemia Drugs Market: Key Players